Sigilon rises after UK allows clinical trial of genetic disorder therapy

Sigilon Therapeutics

09/09/2021 17:28

** Shares of drug developer  SGTX.O  rise 3.6% to $6.13
    ** Sigilon Therapeutics says U.K regulators accepted its
application to start a clinical trial of its experimental
therapy, SIG-005, for Mucopolysaccharidosis Type I (MPS-1)
 urn:newsml:reuters.com:*:nGNX9qzP8l
    ** MPS-1 is a progressive disorder caused by a genetic
mutation which affects several parts of the body
    ** Co says, with the approval, it remains on track to
initiate its early-to-mid stage study in the UK in the second
half of this year
    ** Says it has also submitted a clinical trial application
for the therapy in Brazil and plans to submit a similar
application with the U.S. FDA
    ** Stock has plunged 87.2% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))